These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 5061301)

  • 1. The use of dihydrofolate reductase as a signal for scheduling optimal treatment with antileukemic agents.
    Hardesty CT; Chen D; Mead JA
    Cancer Res; 1972 Mar; 32(3):458-61. PubMed ID: 5061301
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluation of antileukemic agents in advanced leukemia L1210 in mice. X.
    Kline I; Gang M; Tyrer DD; Venditti JM; Artis EW; Goldin A
    Cancer Chemother Rep 2; 1972 Nov; 3(1):1-69. PubMed ID: 4660732
    [No Abstract]   [Full Text] [Related]  

  • 3. Lack of intracellular conversion of dihydrohomofolate to tetrahydrohomofolate in leukemia cells with high levels of dihydrofolate reductase.
    Nahas A; Friedkin M
    Mol Pharmacol; 1972 May; 8(3):353-61. PubMed ID: 5040933
    [No Abstract]   [Full Text] [Related]  

  • 4. [L 1210 leukemia, an experimental model for the potentiation of drugs used for acute leukemias].
    Pouillart P; Huong TH; Lhéritier J
    Bull Cancer; 1974; 61(4):509-26. PubMed ID: 4458834
    [No Abstract]   [Full Text] [Related]  

  • 5. Circadian optimization of the treatment of L1210 leukemia with 1-beta-D-arabinofuranosylcytosine, cyclophosphamide, vincristine and methylprednisolone.
    Burns ER; Scheving LE
    Chronobiologia; 1980; 7(1):41-51. PubMed ID: 7438892
    [No Abstract]   [Full Text] [Related]  

  • 6. Sequential administration of two oncostatic drugs: study of modalities for pharmacodynamic potentiation.
    Pouillart R; Huong TH; Brugerie E; Lheritier J
    Biomedicine; 1974 Dec; 21(12):471-9. PubMed ID: 4462870
    [No Abstract]   [Full Text] [Related]  

  • 7. Combined therapy of L1210 leukemia with Damvar and cytostatics.
    Pujman V; Cernochová S
    Neoplasma; 1979; 26(5):521-3. PubMed ID: 522924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variation of dihydrofolate reductase activity during in vitro and in vivo growth of sublines of L1210 lymphoma.
    Hillcoat BL
    J Natl Cancer Inst; 1971 Jan; 46(1):75-80. PubMed ID: 5546195
    [No Abstract]   [Full Text] [Related]  

  • 9. The basis for the disparate sensitivity of L1210 leukemia and Walker 256 carcinoma to a new triazine folate antagonist.
    Skeel RT; Sawicki WL; Cashmore AR; Bertino JR
    Cancer Res; 1973 Nov; 33(11):2972-6. PubMed ID: 4748449
    [No Abstract]   [Full Text] [Related]  

  • 10. Rationale of chemotherapeutic adjuvant treatment.
    Goldin A
    Arch Geschwulstforsch; 1978; 48(7):627-35. PubMed ID: 736743
    [No Abstract]   [Full Text] [Related]  

  • 11. Immunologic heterogeneity of dihydrofolate reductase from methotrexate sensitive and resistant L1210 leukemia cells.
    Iqbal MP; Rothenberg SP; Larosa C
    Proc Soc Exp Biol Med; 1985 Oct; 180(1):98-102. PubMed ID: 2412235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implications of biochemical, cytokinetic, pharmacologic, and toxicologic relationships in the design of optimal therapeutic schedules.
    Skipper HE; Schabel FM; Mellett LB; Montgomery JA; Wilkoff LJ; Lloyd HH; Brockman RW
    Cancer Chemother Rep; 1970 Dec; 54(6):431-50. PubMed ID: 5527023
    [No Abstract]   [Full Text] [Related]  

  • 13. Effectiveness of antitumor agents administered subcutaneously to L1210 leukemic mice in silicone rubber devices.
    Neil GL; Scheidt LG; Kuentzel SL; Moxley TE
    Chemotherapy; 1973; 18(1):27-40. PubMed ID: 4681847
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacologic aspects of homofolate derivatives in relation to amethopterin-resistant murine leukemia.
    Mead JA; Goldin A; Kisliuk RL; Friedkin M; Plante L; Crawford EJ; Kwok G
    Cancer Res; 1966 Nov; 26(11):2374-9. PubMed ID: 4959533
    [No Abstract]   [Full Text] [Related]  

  • 15. A nonfunctional protein in human leukemia cells reacts with antiserum to dihydrofolate reductase from L1210 leukemia cells.
    Iqbal MP; Rothenberg SP
    Life Sci; 1981 Aug; 29(7):689-96. PubMed ID: 6168882
    [No Abstract]   [Full Text] [Related]  

  • 16. [Effect of combination chemotherapy of nitrosourea MCNU with various anti-tumor agents].
    Ninomiya K; Sekido S; Araki T
    Gan To Kagaku Ryoho; 1984 Jun; 11(6):1315-23. PubMed ID: 6428326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypothetical mechanism of therapeutic synergism induced by the combination of 6-thioguanine and 3-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-1-(2-chloroethyl)-1-nitrosourea hydrochloride.
    Fujimoto S; Ogawa M; Sakurai Y
    Cancer Res; 1982 Oct; 42(10):4079-85. PubMed ID: 6955008
    [No Abstract]   [Full Text] [Related]  

  • 18. Current status of new agents.
    Carter SK
    Cancer Chemother Rep 3; 1972 May; 3(1):33-47. PubMed ID: 4116662
    [No Abstract]   [Full Text] [Related]  

  • 19. Identification of a high-molecular-weight nonfunctional protein in L1210 leukemia cells with common antigenic determinants to dihydrofolate reductase.
    Rothenberg SP; Iqbal MP
    Cancer Res; 1983 Feb; 43(2):529-35. PubMed ID: 6184148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of antileukemic (L1210) treatment schedule on disposition of (minus)-emetine hydrochloride (NSC 33669) in normal and leukemic mice.
    Auletta AE; Gery AM; Mead JA
    Cancer Res; 1974 Jul; 34(7):1581-5. PubMed ID: 4833911
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.